bluuebunny/crossref_metadata_2025_split huggingface dataset:
Comparison of growth and drug response of human tumor cells in serum‐free and serum‐supplemented media in human tumor‐clonogenic assay
Authors: Zirvi Karimullah A. , Hill George J. 
Published: February 2007

AbstractA comparison was made of growth and drug‐response of five human tumor cell lines (HT‐29, colon carcinoma; TWI, melanoma; A‐549, lung carcinoma; Panc‐1, pancreatic carcinoma; and EJ, bladder carcinoma) in serum‐free media (SFM) and in serum‐supplemented media (SSM) using the human tumor‐clonogenic assay (HTCA) system. HT‐29 cells, which had the highest plating efficiency in both SFM and SSM, were used to obtain dose‐response curves for four drugs (adriamycin, 5‐fluorouracil, cisplatin, and BCNU) in the HTCA. Three of the drugs (adriamycin, 5‐fluorouracil, and cisplatin) produced identical drug‐response curves in both SFM and SSM. These results suggest that, for some chemotherapeutic agents, results comparable to those obtained with SSM in the HTCA can be achieved using SFM. Step‐by‐step addition of growth factors and hormones to SFM may be a useful technique to improve some of the technical and logistic problems associated with the HTCA.
Primary fallopian tube carcinoma: Treatment and spread pattern
Authors: Yoonessi Mahmood , Leberer Joseph P. , Crickard Kent 
Published: February 2007

AbstractThe clinopathologic aspects of seven cases of Fallopian tube adenocarcinoma are analyzed. Potential early spread of this malignancy to the retroperitoneal lymph nodes and right subdiaphragmatic area is documented. Multimodality treatment of tubal cancer to include surgery, radiation, and drug therapy (alkylating agents, progestins, with or without 5‐fluorouracil and adriamycin) appears feasible and promising.
Multiple head and neck neoplasia following radiation for benign disease during childhood
Authors: Sirota David K. , Eden Avrim R. , Biller Hugh F. 
Published: February 2007

AbstractA woman received radiation therapy to the adenoids for benign disease at the age of 10 years and subsequently developed an adenocarcinoma of the middle ear, a parathyroid adenoma, and a papillary carcinoma of the thyroid gland in adulthood. This appears to be the first such case on record. The literature of neoplasia after head and neck irradiation is briefly reviewed.
Adenylate cyclase activity and cyclic adenosine monophosphate levels in colon cancer lines and dermal fibroblasts and the effects of cholera toxin and epidermal growth factor
Authors: Nelson Richard L. , Holian Oksana 
Published: February 2007

AbstractThe intracellular concentration and rate of cyclic adenosine monophosphate (cAMP) synthesis, as measured by adenylate cyclase (AC) activity, were measured in dermal fibroblast cultures, colon cancer lines, and cells cultured from colonic epithelium and colonic adenomas. Dermal fibroblasts had higher AC activity and intracellular cAMP levels than the colon cancer lines (p < 0.05). Benign colonic epithelial cultures (mucosa and adenomas) had AC levels similar to those found in dermal fibroblasts. To characterize further these observed differences, similar measurements were made in cultures incubated in cholera toxin (CT) or epidermal growth factor (EGF). CT stimulated AC activity and cAMP accumulation in both cancers and fibroblasts. EGF had no effect on AC activity in cancers or fibroblasts, and no effect on cAMP concentration in cancer, although EGF incubation did increase intracellular cAMP in fibroblasts. Dermal fibroblasts from colon cancer‐prone patients had AC activity and cAMP concentration not significantly different, though greater, than fibroblasts from healthy individuals. Therefore, although the product of the oncogene associated with colon cancer has been shown to be an activator of AC in yeast, in human colon cancer, AC activity and intracellular cAMP concentration were much lower than in dermal fibroblasts. This difference was so great that AC activity and intracellular concentration of cAMP might be biochemical markers that can be used to differentiate colon cancer from benign cells in tissue culture.
Treatment of pulmonary mycosis fungoides with whole‐lung radiation therapy
Authors: Patel Dhirendra J. , Griem Melvin L. , Vijayakumar Srinivasan , Griem Sylvia F. 
Published: February 2007

AbstractVisceral involvement is a relatively common but poorly appreciated occurrence in patients with mycosis fungoides. The lungs are the most common site of visceral involvement. Here we present two cases of mycosis fungoides with pulmonary parenchymal involvement, one of them proven by biopsy. Both patients were treated with whole‐lung radiation therapy, with complete disappearance of the lesions and improvement of respiratory symptoms. There was no significant radiation‐induced pulmonary toxicity. One patient continues to be alive with no recurrence in the lungs 17 months after radiation therapy.
Intraoperative irradiation in a rat model: Histopathological changes in irradiated segments of duodenum
Authors: Poulakos Lawrence , Elwell James H. , Osborne James W. , Urdaneta Luis F. , Hauer‐Jensen Martin , Vigliotti Antonio P. , Hussey David H. , Summers Robert W. 
Published: February 2007

AbstractDuring intraoperative radiation therapy for carcinoma of the head of the pancreas in humans, a portion of duodenum is often at risk for radiation‐induced complications because of its fixed anatomical position within the treatment field. This study was undertaken to determine the feasibility of using the rat as a model to determine the radiotolerance of normal mammalian duodenum. The procedures used to exteriorize and irradiate a selected segment of duodenum are described. Histopathologic changes in 5‐cm segments of midduodenum were studied 14 and 28 days after 0, 30, 40, or 50 Gy X‐radiation. Complete denudation of the epithelium and thickening of the muscularis and serosal layers occurred in all irradiated segments by day 14. By day 28, even though crypt and villus architectures were atypical, large areas of epithelial regeneration were seen in rats receiving 30 Gy. In contrast, complete denudation of the epithelium were still evident along most of the length of the irradiated segments in rats receiving 40 or 50 Gy. Serosal fibrosis was prominent in all irradiated animals, regardless of dose. These results indicate that radiation doses above 30 Gy carry high risks of complications. The rat is considered a suitable animal model.
Clinicopathologic study of esophageal cancer associated with simultaneous metastatic lesions in the stomach
Authors: Maeta Michio , Koga Shigemasa , Shimizu Norio , Hamazoe Ryuichi , Inoue Yasuhiro 
Published: February 2007

AbstractBetween 1965 and 1985, 89 Japanese patients with esophageal squamous cell carcinoma underwent esophagectomy. In five of them (5.6%), a simultaneous metastatic lesion from the esophageal cancer was detected within the stomach in the resected specimens. Preoperative diagnosis of the gastric lesions had been made in none of the five patients because of an obstruction that was due to esophageal cancer. All gastric lesions were located at the gastric cardia, close to the esophagocardial junction, with a mean distance of 6.9 ± 2.0 cm from the primary esophageal lesions. Provision of a gastric tube that contains metastatic lesions, for reconstruction of a new alimentary tract after esophagectomy, must be avoided. In cases of inadequate preoperative gastric examination, gastric lesions should be searched for intraoperatively, not only by serosal inspection and palpation, but also by mucosal inspection and palpation after partial proximal gastrectomy.
Demonstration of a well‐characterized tumor‐associated antigen on melanoma cell surface
Authors: Wong Jan H. , Gupta Rishab K. , Morton Donald L. 
Published: February 2007

AbstractWe have isolated and characterized a melanoma tumor‐associated antigen (TAA) from the spent culture medium of a melanoma cell line. Its presence has been detected in 72% of different melanoma specimens but not in normal tissues. Because tumor antigens may stimulate or perhaps block immune reactions to cancer cells, their presence on the cell surface may be a critical factor influencing tumor growth. Therefore, to define further the immunobiological characteristics of melanoma TAA, this antigen was investigated by membrane immunofluorescence. Serum from a melanoma patient known to have a high anti‐TAA antibody titer was absorbed quantitatively with lymphoblastoid cells autologous to the target melanoma cells to remove non‐anti‐TAA antibodies. The absorbed serum was reacted with three cultured melanoma cell lines, UCLA‐SO‐10 (M10), UCLA‐SO‐14(M14), and UCLA‐SO‐24 (M24). Of these cell lines, M10 and M14 are known to express the antigen as assessed by radioimmunoassay. Reaction of the antibody(s) to the antigen(s) on the melanoma cell surface was detected by fluoroscein‐conjugated goat anti‐human IgG. The reactivity of the absorbed serum was inhibited by preincubation with purified melanoma TAA. These results clearly demonstrate that melanoma TAA is expressed on the cell surface of cultured melanoma cells.
Unresectable retroperitoneal malignant fibrous histiocytoma: Prolonged complete remission following chemoradiotherapy
Authors: Tucci E. , Leoncini L. , Pirtoli L , Guarnieri A. 
Published: February 2007

AbstractTwo cases of unresectable retroperitoneal malignant fibrous histiocytoma (MFH) achieving a prolonged complete remission by a combination of chemotherapy (adriamycin plus cyclophosphamide) and abdominal irradiation are reported. Although an optimal treatment policy for such cases has not been established, on the basis of data currently available, chemotherapy regimens including anthracyclines seem the most reliable therapeutic approach in unresectable and/or metastatic MFH.
Antitumor activity of regional lymph node lymphocytes in patients with lung cancer
Authors: Yaita Hidemichi , Yasumoto Kosei , Nagashima Akira , Sugimachi Keizo , Nomoto Kikuo 
Published: February 2007

AbstractCytotoxic activities of regional lymph node lymphocytes (RLNL) and peripheral blood lymphocytes (PBL) of 49 primary lung cancer patients who were subjected to surgical resection were examined by 4 h 51Cr release assay. PBL showed significantly lower cytotoxicity against autologous tumor cells than against K562 and QG‐56. On the other hand, RLNL exhibited the same level of cytotoxicity against autologous tumor cells as PBL, although the cytotoxicities against K562 and QG‐56 were low. Cytotoxicity of RLNL against autologous tumor cells exhibited a significant degree of depression with the advance of stage, T and N factors. Cytotoxicity of PBL did not significantly change as the stage progressed. When both PBL and RLNL were cultured with purified interleukin‐2 (p‐IL2) in vitro, their cytotoxic activities were markedly augmented and the cytotoxicities could not be diminished by the treatment with anti‐Leu‐7 + anti‐Leu‐11b + C'. These facts indicate that the augmented cytotoxicity may be due to lymphokine activated killer (LAK) cells.
Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin‐vinblastine‐bleomycin chemotherapy
Authors: Gelderman W. A. H. , Koops H. Schraffordt , Sleijfer D. T. H. , Oosterhuis J. W. , Homan Heide J. N. Van Der , Mulder N. H. , Marrink J. , De Bruyn H. W. A. , Oldhoff J. 
Published: February 2007

AbstractFrom January 1978 to April 1983, 53 patients were treated with cisplatin‐vinblastine‐bleomycin chemotherapy because of advanced nonseminomatous testicular tumor (NSTT). After the chemotherapy, the serum tumor markers were back to normal in 41 patients, of whom 35 were eligible for surgical removal of the residual tumor. In four patients, vital tumor tissue was found in the residual tumor. Salvage chemotherapy resulted in complete remission. Residual mature teratoma was encountered after the chemotherapy in 15 of the 25 patients with a teratomatous component and in one of the ten patients without a teratomatous component in the primary tumor. On completion of the study, 38 of the 53 patients (72%) are still alive, with a median follow‐up of 65 months. Subdivided by tumor volume, survival is found to amount to 92% for small‐volume disease, 67% for large‐volume disease, and 64% for very‐large‐volume disease. Six patients (11%) developed a recurrence in the course of the follow‐up. Exploratory laparotomy after remission induction chemotherapy is necessary in all patients with a teratomatous component in the primary testicular tumor who have become tumor marker negative, irrespective of the roent‐genographic findings of the retroperitoneum. Patients without a teratomatous component in the primary tumor should have exploratory laparotomy only in case of roentgenographic evidence of retroperitoneal residual tumor. A thoracotomy is needed only in the presence of roentgenographic evidence of pulmonary residual lesions.
Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas
Authors: Piver M. Steven , Lele Shashikant B. , Marchetti David L. , Emrich Lawrence J. 
Published: February 2007

AbstractWe have evaluated the effect of adjuvant chemotherapy on time to recurrence and survival in two prospective trials of women with stage I uterine sarcomas. The first trial compared surgery only to surgery plus Adriamycin. The 5‐year estimated survival rate was 36% for surgery alone and 63% for surgery plus Adriamycin. The 5‐year recurrence free rate for surgery alone was 46% as compared to 75% for surgery plus Adriamycin. The second trial, without a concurrent control group, included patients with stage I uterine sarcoma and adjuvant cyclaphosphamide, vincristine, Adriamycin, and dacarbazine (CYVADIC) chemotherapy. The 5‐year survival rate was 89% and the recurrence‐free rate was 80%. In all of these trials, as well as in the report of Van Nagell et al (Cancer 57:1451–1454, 1986) of adjuvant vincristine, actinomycin‐D, and cyclophosphamide (VAC) chemotherapy, there are too few patients to make any formal statistical comparison of the groups, although the surgery plus CYVADIC group appears to be the most promising.
Lymphangiosarcoma in postmastectomy lymphedema (Stewart‐Treves syndrome): Ultrastructural and immunohistologic characteristics
Authors: Tomita Katsuro , Yokogawa Akio , Oda Yoshio , Terahata Shintaro 
Published: February 2007

AbstractTwo cases of lymphangiosarcoma arising in a chronic lymphedematous extremity following mastectomy (Stewart‐Treves syndrome) were reported with not only standard histology, but also special study on the ultrastructure and immunohistology. These cancers developed as a result of chronic lymphedema of the involved limb following mastectomy 15 and 16 years ago, respectively, for breast carcinoma. Immunohistologic and electron microscopic examinations proved that this tumor originates in the vascular endotheliocytes, even though they are clinically chronic lesions apparently derived from the lymphatic vessels. This sarcoma develops multicentrically in an edematous arm and spreads out rapidly, so prognosis is quite discouraging in those patients. They need to be radically surgically treated without hesitation; hence, amputation, not limb‐saving surgery, should be indicated.
Adriamycin‐vitamin E combination therapy for treatment of prostate adenocarcinoma in the NB rat model
Authors: Nesbitt John A. , Smith Jeffery , McDowell Gladstone , Drago Joseph R. 
Published: February 2007

AbstractAdriamycin used in combination with vitamin E (Tocopherol) was evaluated in the treatment of Nb rat prostate adenocarcinoma. Vitamin E has been shown to enhance the growth‐inhibitory effects of adriamycin on human prostatic carcinoma cells in vitro. The adriamycin‐vitamin E treatment groups had the lowest average final tumor volume, but the mortality rate was 57% (17/30). These results suggest that vitamin E may play a role in enhancing the cytotoxic effects of adriamycin, but may not have any protective effect on normal cells as previously suggested through in vitro methods.
Rapidly growing mature teratoma of the mediastinum: Do sex hormones affect growth of the tumor?
Authors: Uyama Tadashi , Monden Yasumasa , Harada Kunihiko , Kimura Suguru , Morimoto Tadaoki , Miura Kazumasa , Taniki Toshikatsu , Tanida Nobuyuki 
Published: February 2007

AbstractThe case of a 12‐year‐old girl with an anterior mediastinal tumor is reported. A mass grew rapidly and occupied the anterior mediastinum after menarche. Resected material was diagnosed as a mature teratoma. Both estrogen receptors and progesterone receptors were detected in the resected tissue. The titer of estrogen receptors was 2–11.3 femtomoles per milligram of protein and that of progesterone receptors was 9.5–15.7 fmol/mg protein. Based on these data, it was surmised that sex hormones may affect the growth of the tumor in this case. The change in sex hormones after menarche may have played a role in the rapid growth of this tumor.
Hepatocellular carcinoma with bone metastasis
Authors: Gattuso Paolo , Reyes Cesar V. 
Published: February 2007

AbstractThe autopsy of hepatocellular carcinoma at Hines VA Hospital was reviewed for a 33‐year period, between 1954 and 1986. The neoplasm is uncommon and bone involvement was observed in 7.3% or in ten of 137 cases. A clinical presentation of osseous metastasis in hepatocellular carcinoma is rare. A brief literature review is also included.
Testicular cancer in young norwegians
Authors: Fosså Sophie Dorothea , Aass Nina , Kaalhus Olav 
Published: February 2007

AbstractThe clinical experience is reviewed in 597 Norwegian testicular cancer patients (age range: 15–45 years) treated from 1979 to 1986. During this period, computer tomography, determination of serum AFP/HCG, and cisplatin‐based chemotherapy represented the modern diagnostic and therapeutic mcdalities. Before orchiectomy 67% of the patients had elevated AFP/HCG. An abnormal postorchiectomy serum tumour marker decrease and the presence of small vessel infiltration in the histological sections of the primary tumour significantly predicted microscopic retroperitoneal metastases in patients with clinical stage I (CSI) nonseminoma. One‐third of these patients had a pathological stage II (PSII). After radiotherapy 99% of 90 seminoma patients (CSI/IIa) survived for 5 years. After cisplatin‐based chemotherapy (+ radiotherapy/surgery) the 5‐year survival rate in 25 patients with advanced seminoma was 81 %. The survival rate in 148 nonseminoma patients PSI/IIa was 100% and 87% in 94 patients with advanced nonseminoma (≥CSIIb). Nausea, general exhaustion, myelosuppression, peripheral neuropathy, and Raynaud‐like phenomena were the main acute treatment‐related side effects. Slight gastrointestinal problems, slight peripheral neuropathy, Raynaud‐like phenomena, and fertility disturbances were frequent late side effects. The sexual life in testicular cancer patients did not seem to be significantly impaired as compared to the normal population. Most of the patients reported no or only slight emotional problems during and after treatment. The need of thorough information at the time of diagnosis was stressed by most of them.Secondary cancer was diagnosed in 27 of 795 patients (1970–1982) (Testicular: 15; pulmonary: 4; sarcoma: 2; others: 6).Testicular cancer is today a curable malignancy. Future clinical research has to concentrate on the identification of high‐risk and low‐risk patients, the avoidance of overtreatment, and the reduction of toxicity (especially of long‐term side effects).
Malignant epithelioid schwannoma: A light microscopic and immunohistochemical study
Authors: Chu Tu‐Anh , Shmookler Barry M. 
Published: February 2007

AbstractMalignant epithelioid schwannoma is a rare variant of malignant nerve sheath tumor that can be confused with both other neuroectodermal neo plasms and carcinomas. The light microscopic and immunohistochemical findings of a malignant epithelioid schwannoma arising in the mandibular region of a 27‐year‐old female are described. The differential diagnosis of this unusual neoplasm from malignant melanoma and poorly differentiated carcinoma is discussed.
Treatment of askin rosai tumor—need for a more aggressive approach
Authors: Parikh P. M. , Charak B. S. , Banavali S. D. , Advani S. H. , Saikia T. K. , Gopal R. , Borces A. M. , Chinoy R. F. , Desai P. B. 
Published: February 2007

AbstractFifteen cases of histologically proven Askin Rosai tumor were treated at Tata Memorial Hospital over a period of 3 years. Patients included 12 men and three women. Clinical features included chest wall mass (14), pain (11), bony involvement (6), fever (4), dyspnoea (4), weight loss (1), cough (1), and hemoptysis (1). Previously treated patients received different treatment protocols, which made evaluation difficult. Of our ten patients who have completed induction therapy, five received vincristine and cyclophosphamide, whereas the other five received more aggressive chemotherapy. Complete remission has been achieved in two and four of these patients, respectively. One patient in each group had recurrence of the disease, in both cases at the local site. Thus, from our preliminary data, we suggest that Askin Rosai tumor should be treated with complete surgical excision followed by an aggressive combination of chemotherapy and local radiotherapy.
Incidental detection of carcinoma of the prostate while staging carcinoma of the rectum with transrectal ultrasound
Authors: Ragde Haakon 
Published: February 2007

AbstractThis case report describes the unanticipated results of a transrectal ultrasound performed to stage a cancer of the rectum. During sonography, the normally dense prostate peripheral zone produced weak echoes indicating the existence of an unexpected carcinoma of the prostate. The presence of extensive prostate cancer was subsequently verified by biopsy.
Two years of cyclophosphamide and 5‐fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma
Authors: Caceres E. , Valdivia S. , Cotrina M. , Lingan M. , Leon L. , Gamboa M. , Olivares L. , Moran M. 
Published: February 2007

AbstractThe results after 6 years of a prospective clinical trial of adjuvant chemotherapy with a regimen of two drugs—cyclophosphamide and 5‐fluorouracil (CF)— for 2 years in 97 women with stage II or III breast cancer are reported. Eligible patients were free from distant metastases. All patients began adjuvant therapy within 4 weeks of surgery; therapy consisted of radical, modified, or extended radical mastectomy. No postoperative radiotherapy was given. The results are compared with a historical control group from previous consecutive patients treated by surgery alone. Patients were stratified by age (younger than 50 or older than or equal to 50) and nodal status (one to three positive axillary nodes vs. four or more positive nodes). The estimated 6‐year survival was 60% for CF patients vs. 31% for control patients (P = 0.001). The estimated 6‐year disease‐free survival was 53.6 and 30.3% for CF and control, respectively (P = 0.007). There was a trend toward longer disease‐free survival (DFS) and survival (S) in patients treated with CF, but this was not significant in all the subgroups. Disease‐free survival was statistically significant in the subgroup of women ≥ 50 years old with one to three positive nodes (P = 0.038); survival in the patients ≤ 49 years old with four or more positive nodes (P = 0.0036); and in patients ≥ 50 years old with one to three lymph nodes involvement (P = 0.038).